ADMS News and Press, Adamas Pharmaceuticals Inc. From 12/02/20

Adamas Pharmaceuticals (ADMS) inks an agreement with Healthcare Royalty Partners amending its royalty-backed loan agreement. Key changes:Revised to provide for repayment from a royalty on OSMOLEX ER (amantadine) on the same terms as, and in addition to, the royalty for GOCOVRI ...

Adamas Pharmaceuticals (ADMS) inks an agreement with Osmotica Pharmaceutical US LLC settling the patent litigation related to Osmolex ER (amantadine).The company will acquire global rights to Osmolex ER for $7.5M.The deal should close next quarter. For further details see: Adamas Pharma...

EMERYVILLE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has entered into an agreement&...

EMERYVILLE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has signed an agreem...

EMERYVILLE, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company&#x...

EMERYVILLE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Spyros Papapetropoul...

EMERYVILLE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company&#x...

Adamas Pharmaceuticals recently reported its Q3 earnings with a slight beat on EPS and a slight miss on revenue. The company did report record product sales for GOCOVRI. Adamas looks to have found a rhythm for GOCOVRI and the commericial numbers continue to improve. In addition,i t is...

Adamas Pharmaceuticals, Inc. (ADMS) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Peter Vozzo – Investor Relations Neil McFarlane – Chief Executive Officer Vijay Shreedhar – Chief Commercial Officer Chris Prentiss – Chief Financi...

Third quarter 2020 total revenues of $20.2 million, a 45% increase over third quarter 2019 Third quarter 2020 GOCOVRI® product sales of $19.0 million, a 36% increase over third quarter 2019 Total paid prescriptions of 7,930, a 19% increase over third quarter 2019 ...